Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10881MR)

This product GTTS-WQ10881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12716MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ10058MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ3463MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ11015MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ14316MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ5994MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ15298MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ1513MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW